UPDATE: Cantor Fitzgerald On Novavax Also Sees Potential Value 'based on Co.'s platform recombinant nanoparticle and Matrix-M adjuvant technologies, including its influenza/RSV programs, its emerging infectious disease programs and licensing of Matrix-M for use in other vaccines.'
Benzinga Newsdesk